The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

Breast and ovarian cancer patients harboring BRCA1/2 germline mutations have clinically benefitted from therapy with PARP inhibitor (PARPi) or platinum compounds, but acquired resistance limits clinical impact. In this study, we investigated the impact of mutations on BRCA1 isoform expression and th...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Cancer Res
المؤلفون الرئيسيون: Wang, Yifan, Bernhardy, Andrea J., Cruz, Cristina, Krais, John J., Nacson, Joseph, Nicolas, Emmanuelle, Peri, Suraj, van der Gulden, Hanneke, van der Heijden, Ingrid, O'Brien, Shane W., Zhang, Yong, Harrell, Maribel I., Johnson, Shawn F., Candido Dos Reis, Francisco J., Pharoah, Paul D. P., Karlan, Beth, Gourley, Charlie, Lambrechts, Diether, Chenevix-Trench, Georgia, Olsson, Håkan, Benitez, Javier J., Greene, Mark H., Gore, Martin, Nussbaum, Robert, Sadetzki, Siegal, Gayther, Simon A., Kjaer, Susanne K., D'Andrea, Alan D., Shapiro, Geoffrey I., Wiest, David L., Connolly, Denise C., Daly, Mary B., Swisher, Elizabeth M., Bouwman, Peter, Jonkers, Jos, Balmaña, Judith, Serra, Violeta, Johnson, Neil
التنسيق: Artigo
اللغة:Inglês
منشور في: 2016
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC4874568/
https://ncbi.nlm.nih.gov/pubmed/27197267
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-0186
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة